Access cutting-edge gastric cancer treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.
Access gastric cancer specialists in Pittsburgh at no cost
This study follows strict safety protocols and ethical guidelines
All study-related gastric cancer treatment provided free
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Phanes Therapeutics
Check if you qualify for this gastric cancer clinical trial in Pittsburgh, PA
If you're searching for gastric cancer treatment options in Pittsburgh, PA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastric cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.